Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
18th August 2025 Uncategorised 0The FDA has signed off on an accelerated approval for Novo Nordisk’s Wegovy to treat certain adults with metabolic-associated steatohepatitis. The green light tees up a likely showdown with Madrigal Pharmaceuticals’ approved drug Rezdiffra in the severe form of fatty liver disease.
More: Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
Source: fierce